Filter By Category
Archives
Share on -
CRINECERFONT
Generic Name: CRINECERFONT
ABSTRACT -
Crinecerfont is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist used as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years and older with classic congenital adrenal hyperplasia (CAH).
DOSAGE -
- Adults: 100 mg orally twice daily with a meal in the morning and evening. Pediatric patients 4 years and older: 10 to <20 kg, 25 mg twice daily.
- 20 to <55 kg, 50 mg twice daily.
- >=55 kg, 100 mg twice daily, with meals. Strong CYP3A4 inducers require doubling both morning and evening doses.
- moderate CYP3A4 inducers require doubling the evening dose only, according to product labeling.
SIDE EEFECTS -
Common adult adverse reactions include fatigue, headache, dizziness, arthralgia, back pain, decreased appetite, and myalgia. Common pediatric adverse reactions include headache, abdominal pain, fatigue, nasal congestion, and epistaxis.
ALLERGIC REACTIONS -
Hypersensitivity including throat tightness, angioedema, and generalized rash has been reported. If a clinically significant hypersensitivity reaction occurs, discontinue crinecerfont and initiate appropriate treatment.
DRUG INTERACTIONS-
Strong or moderate CYP3A4 inducers reduce crinecerfont exposure and require dosage modification. Review all prescription drugs, over-the-counter drugs, and herbals, and avoid unsupervised changes to glucocorticoid therapy.
PREAUTONS–
Crinecerfont is adjunctive therapy and does not replace glucocorticoid replacement for adrenal insufficiency. Do not reduce glucocorticoid dosage below replacement needs. Monitor androgen control, adrenal insufficiency symptoms, and adrenal-crisis risk, especially during illness or dose changes.
WARNINGS –
Adrenal insufficiency or adrenal crisis may occur if glucocorticoid replacement is inadequate. Clinically significant hypersensitivity requires discontinuation.
Share on -
. Developed by